Shares of Roivant Sciences have moved -1.0% today, and are now trading at a price of $10.69. In contrast, the S&P 500 index saw a -0.0% change. Today's trading volume is 19,405,106 compared to the stock's average volume of 6,795,906.
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. Based in London, United Kingdom the company has 908 full time employees and a market cap of $7,896,937,472.
The company is now trading -35.87% away from its average analyst target price of $16.67 per share. The 9 analysts following the stock have set target prices ranging from $12.0 to $20.0, and on average give Roivant Sciences a rating of buy.
Over the last 52 weeks, ROIV stock has risen 16.4%, which amounts to a -9.8% difference compared to the S&P 500. The stock's 52 week high is $13.24 whereas its 52 week low is $8.24 per share. Based on Roivant Sciences's average net margin growth of 19.3% over the last 4 years, its core business is on track for profitability and its strong stock performance may continue in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) |
|---|---|---|---|
| 2023 | 124,795 | 4,348,926 | |
| 2022 | 61,280 | -1,009,030 | -1647 |
| 2021 | 55,286 | -845,262 | -1529 |
| 2020 | 23,795 | -809,234 | -3401 |
